Richard Stone, MD: New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AML

The FLT3 inhibitor crenolanib, when added to standard induction chemotherapy, was associated with high rates of minimal residual disease negativity in patients with FLT3-mutated acute myeloid leukemia. Dr. Stone shares results from the ongoing phase II trial.

SHARE